Remicade: Of Late, Biosimilars Have Gained Share at Greater Clip, But Overall Picture Shows Problematic Biosimilar Adoption Rate; Antitrust Lawsuits Provide Context for FTC Investigation

Published on Jul 11, 2023

The Capitol Forum recently published an analysis of market share and pricing data for the blockbuster autoimmune disorder treatment Remicade (infliximab), which has been under FTC investigation since 2019. Our reporting exposed a broken system in which rebate schemes appear to drive market share for Remicade and its biosimilar competitors. Remicade, marketed by Johnson & […]

Already have an account? Log in.

This article is currently locked and only available to subscribers. Request a trial to receive unlimited access to all articles.

View Only Unlocked Articles

© 2024 the Capitol Forum